- Home
- ADPT vs CSAN Comparison
ADPT vs CSAN Comparison
Compare ADPT & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- CSAN
- Stock Information
- Founded
- ADPT 2009
- CSAN 1936
- Country
- ADPT United States
- CSAN Brazil
- Employees
- ADPT N/A
- CSAN N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- CSAN Retail-Auto Dealers and Gas Stations
- Sector
- ADPT Health Care
- CSAN Consumer Discretionary
- Exchange
- ADPT Nasdaq
- CSAN Nasdaq
- Market Cap
- ADPT 2.0B
- CSAN 2.1B
- IPO Year
- ADPT 2019
- CSAN N/A
- Fundamental
- Price
- ADPT $15.53
- CSAN $4.27
- Analyst Decision
- ADPT Strong Buy
- CSAN Hold
- Analyst Count
- ADPT 10
- CSAN 3
- Target Price
- ADPT $13.60
- CSAN $9.47
- AVG Volume (30 Days)
- ADPT 2.0M
- CSAN 2.4M
- Earning Date
- ADPT 11-06-2025
- CSAN 11-12-2025
- Dividend Yield
- ADPT N/A
- CSAN N/A
- EPS Growth
- ADPT N/A
- CSAN N/A
- EPS
- ADPT N/A
- CSAN N/A
- Revenue
- ADPT $205,216,000.00
- CSAN $7,993,490,490.00
- Revenue This Year
- ADPT $32.63
- CSAN $270.07
- Revenue Next Year
- ADPT $16.31
- CSAN $1.31
- P/E Ratio
- ADPT N/A
- CSAN N/A
- Revenue Growth
- ADPT 21.60
- CSAN 7.98
- 52 Week Low
- ADPT $4.27
- CSAN $3.80
- 52 Week High
- ADPT $15.94
- CSAN $8.79
- Technical
- Relative Strength Index (RSI)
- ADPT 66.13
- CSAN 38.89
- Support Level
- ADPT $14.11
- CSAN $4.11
- Resistance Level
- ADPT $15.26
- CSAN $4.56
- Average True Range (ATR)
- ADPT 0.73
- CSAN 0.17
- MACD
- ADPT 0.12
- CSAN -0.08
- Stochastic Oscillator
- ADPT 87.90
- CSAN 15.76
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.